High Tide - CEO, Raj Grover.
CEO, Raj Grover.
Source: LinkedIn.
  • High Tide (HITI) has opened two new locations under its Canna Cabana brand
  • The stores in North York and Winnipeg bring the total of Canna Cabana brick-and-mortar locations to 147
  • The company plans to open additional stores before the end of the year
  • High Tide is Canada’s largest non-franchised cannabis retail chain
  • High Tide (HITI) opened unchanged, trading at $1.98 per share

High Tide (HITI) has opened two new locations under its Canna Cabana brand.

The stores in North York and Winnipeg bring the total of Canna Cabana brick-and-mortar locations to 147.

Situated near a major Ontario grocer and a national pharmacy chain, the North York Canna Cabana is a short drive from York University. The surrounding community is also one of Toronto’s most densely populated.

The Winnipeg store is located within the St. Vitals mall, which houses major international retailers alongside multiple dining and entertainment options. The store is also situated near a main thoroughfare.

“As I have said before, our retail strategy involves finding the best available real estate in high-traffic and high-population-density areas, and both of these stores showcase our commitment to this strategy,” stated Raj Grover, President and CEO of High Tide. “This selective real estate approach has served us well, as demonstrated by the fact that our average per-store sales in Ontario are more than double the provincial average.”

“We remain on track to announce several additional store openings before the end of this year, which will get us very close to, if not reaching, our goal of 150 stores across Canada by the end of 2022,” he added.

High Tide is Canada’s largest non-franchised cannabis retail chain.

High Tide (HITI) opened unchanged, trading at $1.98 per share.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.